Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GlycoScientific is a private U.S. glycobiology tools company focused on developing and commercializing research reagents for glycan analysis and protein glycosylation characterization. Its offerings include stable isotope-labeled glycan standards, glycoprotein quantitation standards, recombinant human IgG standard proteins, and antibodies against site-specific O-GlcNAc and O-fucose modified proteins. The company appears to serve research and disease-diagnostics related applications rather than developing therapeutic drug candidates. GlycoScientific's best-known platform/product is iGlycoMab, a monoclonal antibody reagent labeled with stable isotopes to support qualitative and quantitative glycan analysis by mass spectrometry. The business is positioned at the intersection of glycobiology, analytical reagents, and immunological research tools.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GlycoScientific.